Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx Appoints Karl Gubitz as Chief Financial Officer
04:01am, Tuesday, 01'st Jun 2021
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, t
argenx to Present at Upcoming Investor Conferences
01:00am, Tuesday, 01'st Jun 2021
June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, t
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call Transcript
03:08pm, Friday, 14'th May 2021
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call Transcript
Recap: argenx Q1 Earnings
07:07am, Friday, 14'th May 2021
Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the esti
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
01:00am, Friday, 14'th May 2021
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)
argenx's Earnings Outlook
12:45pm, Thursday, 13'th May 2021
argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.
argenx announces results of Annual General Meeting of Shareholders
05:00am, Tuesday, 11'th May 2021
May 1 1 , 20 2 1 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and ca
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
01:00am, Friday, 07'th May 2021
May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, to
argenx Management to Present at Upcoming Virtual Investor Conferences
01:00am, Wednesday, 28'th Apr 2021
April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,
argenx announces Annual General Meeting of Shareholders on May 11, 2021
04:00pm, Tuesday, 30'th Mar 2021
March 30, 2021
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call Transcript
03:18pm, Thursday, 04'th Mar 2021
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call Transcript
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
01:00am, Thursday, 04'th Mar 2021
- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
01:00am, Thursday, 25'th Feb 2021
February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and canc
argenx announces closing of global offering
04:01pm, Friday, 05'th Feb 2021
Regulated information
argenx announces full exercise of underwriters' option to purchase additional ADSs
01:00am, Thursday, 04'th Feb 2021
Regulated information — Inside information
